Key terms
About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JNJ news
Today
8:06am ET
RBC Capital Sticks to Its Buy Rating for Johnson & Johnson (JNJ)
Yesterday
4:55am ET
Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3
May 31
8:50am ET
Johnson & Johnson completes Shockwave acquisition, sees EPS dilution
May 30
4:52pm ET
Vanda Pharma completes transfer of FDA Marketing Authorization for Ponvory
May 30
9:59am ET
PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
May 30
7:41am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT), Johnson & Johnson (JNJ) and American Well (AMWL)
May 30
7:26am ET
Johnson & Johnson reinstated with a Neutral at Goldman Sachs
May 29
5:18pm ET
Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3
May 29
8:28am ET
Johnson & Johnson reports seltorexant met endpoints in MDD3001 clinical trial
May 29
5:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM), Arcturus Therapeutics (ARCT) and Johnson & Johnson (JNJ)
May 28
3:57pm ET
Needham medtech/diagnostic analyst holds analyst/industry conference call
May 28
10:10am ET
M&A News: JNJ Snaps Up Ezcema Drug Maker Yellow Jersey for $1.25B
May 28
7:33am ET
Johnson & Johnson to acquire NM26 from Numab for $1.25B in cash
May 24
1:50am ET
Optimistic Buy Rating for JNJ’s Tremfya Based on Strong Market Penetration Potential in IBD
May 22
6:27am ET
RBC Capital Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
May 21
4:48pm ET
Nanobiotix provides update on NBTXR3 collaboration
May 21
4:29pm ET
ShockWave Medical says HSR Act waiting period expired on May 20
May 21
3:35pm ET
Buy Recommendation for Johnson & Johnson on Promising Tremfya Clinical Data and Market Expansion Potential
May 21
8:26am ET
J&J reports Tremfya demonstrates superiority versus Stelara in Crohn’s trial
May 20
7:17am ET
Citi Keeps Their Buy Rating on Johnson & Johnson (JNJ)
May 20
6:02am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)
May 19
7:36am ET
Ex-Dividend Date Nearing for These 10 Stocks – Week of May 20, 2024
May 16
7:36am ET
Johnson & Johnson to acquire Proteologix for $850M in cash
May 16
6:31am ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)
May 16
6:30am ET
Johnson & Johnson (JNJ) Receives a Buy from RBC Capital
May 14
4:52pm ET
Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study
May 13
12:01pm ET
Johnson & Johnson Will Sell Remaining Stake in Kenvue (NYSE:KVUE)
May 13
6:48am ET
Kenvue confirms launch of 182.33M secondary offering for holders
May 09
7:17am ET
Rani Therapeutics price target raised to $14 from $7 at BTIG
May 09
6:47am ET
Hold Rating on Johnson & Johnson Amid Varipulse PFA Catheter Recall and Approval Uncertainties
May 08
12:00am ET
Buy Rating Affirmed: Johnson & Johnson’s Bladder Cancer Treatments Poised to Transform Standard of Care
No recent press releases are available for JNJ
JNJ Financials
Key terms
Ad Feedback
JNJ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
JNJ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
